The effects of bisphosphonate on the remodeling of different irregular bones in mice. (5th November 2014)

• Record Type: Journal Article
• Authors: Su, Jiansheng; Feng, Mu; Han, Wenfei; Zhao, Hang
• Is Part Of: Journal of oral pathology & medicine. Volume 44:Number 8(2015:Sep.)
• Page Start: 638
• Page End: 648
• Publication Date: 2014-11-05
• Subjects: Dentistry -- Periodicals; Teeth -- Diseases -- Periodicals; 617
• DOI: 10.1111/jop.12281
• Languages: English
• ISSNs: 0904-2512

Abstract

<abstract abstract-type="main" id="jop12281-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jop12281-sec-0001" sec-type="section"> <title>Background</title> <p>We aimed to compare the effects of bisphosphonate on the remodeling of irregular bones (the jaw and ilium) in mice after trauma.</p> </sec> <sec id="jop12281-sec-0002" sec-type="section"> <title>Methods</title> <p>To verify the feasibility of modeling osteonecrosis, 20 mice were injected intraperitoneally with zoledronate and dexamethasone (ZOL&DEX group), dexamethasone (DEX group), or phosphate‐buffered saline (PBS) [control (CTR) group]. Mice then underwent extraction of the right maxillary first molar and creation of an artificial bony cavity in the ilium. Bone sections were stained with H&E for morphological studies. To further compare differences between the maxilla and the ilium caused by similar traumas, 80 mice were injected intraperitoneally with ZOL&DEX or PBS. Pathological progression at the injury sites was assessed at 1 day and at 1, 3, and 8 weeks after trauma using micro‐computed tomography (CT), H&E and immunohistochemistry analyses, high‐performance liquid chromatography–mass spectrometry, and enzyme‐linked immunosorbent assay.</p> </sec> <sec id="jop12281-sec-0003" sec-type="section"> <title>Results</title> <p>Only the ZOL&DEX model group effectively developed osteonecrosis. Bony sequestra, osseous sclerosis, unhealed mucosa, and radiopaque alveolar bone were found in the maxilla. In the ilium, there was a lower frequency of osteonecrotic disease and osseous sclerosis, and less suppression of bone remodeling than in the maxilla following long‐term bisphosphonate administration. Zoledronate levels were higher in the maxilla. ZOL&DEX treatment suppressed the levels of RANKL and IL‐17, but induced an upregulation of osteoprotegerin and FAM20C in both bones.</p> </sec> <sec id="jop12281-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Accumulation of bisphosphonate may increase the incidence of osteonecrosis. The RANKL/OPG pathway and IL‐17 and FAM20C cytokines play key roles in the progression of pathologically abnormal bone remodeling.</p> </sec> </abstract>